Financiere de Tubize SA - ESG Rating & Company Profile powered by AI
The report of Financiere de Tubize SA leverages information from across the internet and also from available filings by Financiere de Tubize SA. The analysis of Financiere de Tubize SA is prepared by All Street Sevva using proprietary Cognitive Robots. The Sustainability rating for Financiere de Tubize SA represents the company's transparency towards the United Nations SDGs.
Financiere de Tubize SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.7; made up of an environmental score of 0.0, social score of 2.3 and governance score of 2.7.
1.7
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1631 | Viewbix Inc | 1.8 | Low |
1631 | dorsaVi Ltd | 1.8 | Low |
1682 | Financiere de Tubize SA | 1.7 | Low |
1682 | C4 Therapeutics Inc | 1.7 | Low |
1682 | Abcellera Biologics Inc | 1.7 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Financiere de Tubize SA have an accelerator or VC vehicle to help deliver innovation?
Does Financiere de Tubize SA disclose current and historical energy intensity?
Does Financiere de Tubize SA report the average age of the workforce?
Does Financiere de Tubize SA reference operational or capital allocation in relation to climate change?
Does Financiere de Tubize SA disclose its ethnicity pay gap?
Does Financiere de Tubize SA disclose cybersecurity risks?
Does Financiere de Tubize SA offer flexible work?
Does Financiere de Tubize SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Financiere de Tubize SA disclose the number of employees in R&D functions?
Does Financiere de Tubize SA conduct supply chain audits?
Does Financiere de Tubize SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Financiere de Tubize SA conduct 360 degree staff reviews?
Does Financiere de Tubize SA disclose the individual responsible for D&I?
Does Financiere de Tubize SA disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Financiere de Tubize SA disclose current and / or historical scope 2 emissions?
Does Financiere de Tubize SA disclose water use targets?
Does Financiere de Tubize SA have careers partnerships with academic institutions?
Did Financiere de Tubize SA have a product recall in the last two years?
Does Financiere de Tubize SA disclose incidents of discrimination?
Does Financiere de Tubize SA allow for Work Councils/Collective Agreements to be formed?
Has Financiere de Tubize SA issued a profit warning in the past 24 months?
Does Financiere de Tubize SA disclose parental leave metrics?
Does Financiere de Tubize SA disclose climate scenario or pathway analysis?
Does Financiere de Tubize SA disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Financiere de Tubize SA disclose the pay ratio of women to men?
Does Financiere de Tubize SA support suppliers with sustainability related research and development?
Does Financiere de Tubize SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Financiere de Tubize SA reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Financiere de Tubize SA involved in embryonic stem cell research?
Does Financiere de Tubize SA disclose GHG and Air Emissions intensity?
Does Financiere de Tubize SA disclose its waste policy?
Does Financiere de Tubize SA report according to TCFD requirements?
Does Financiere de Tubize SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Financiere de Tubize SA disclose energy use targets?
Does Financiere de Tubize SA disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Financiere de Tubize SA have a policy relating to cyber security?
Have a different question?
Potential Risks for Financiere de Tubize SA
These potential risks are based on the size, segment and geographies of the company.
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.